[Primary ano-rectal melanoma].

Chir Ital

Divisione VII: Chirurgia Gastroenterologica, Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli, Napoli.

Published: March 2001

Primary malignant anorectal melanoma is an uncommon disease that accounts for 1% of anorectal malignancies. Its virulent malignancy is associated with a poor prognosis and with difficult diagnostic and therapeutic problems. The operative management of these patients is controversial. Clinicopathologic features and surgical treatment of 6 patients with primary anorectal melanoma were studied retrospectively. There was a male preponderance (2:1) with a mean age of 62 years (range: 34-74). The site of origin of the melanoma was rectal in one patient and in the anorectal junction in five patients. Atypical intramucosal melanocyte proliferation was associated with rectal melanoma. The maximum tumor size from 2 to 5.5 cm. Common initial symptoms were rectal bleeding and/or tenesmus. CT was useful for tumor staging. Two patients had distant metastases at initial presentation. Four patients underwent "curative" treatments by abdominoperineal resection and 2 by local excision. The survival for the group as a whole was poor (mean: 12.6 months; range: 7-30 months). Surgery is the primary option. The prognosis, however, is poor, since metastatic disease is commonly established at presentation. Atypical intramucosal melanocyte proliferation may be a marker in association with tumor sited in the rectum.

Download full-text PDF

Source

Publication Analysis

Top Keywords

anorectal melanoma
8
atypical intramucosal
8
intramucosal melanocyte
8
melanocyte proliferation
8
patients
5
[primary ano-rectal
4
ano-rectal melanoma]
4
melanoma] primary
4
primary malignant
4
anorectal
4

Similar Publications

Introduction: Anorectal melanoma (ARM) is rare and highly lethal neoplasm. It has a poorer prognosis compared with cutaneous ones. Sentinel lymph node biopsy (SLNB) has become the preferred method of nodal staging method for cutaneous melanoma.

View Article and Find Full Text PDF

Real-World Evidence of the Prevalence of Driver Mutations in Anorectal Melanoma.

Mol Diagn Ther

December 2024

Comprehensive Cancer Center, University of Maastricht, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX, Maastricht, The Netherlands.

Introduction: Anorectal melanoma is a rare neoplasm with an aggressive behavior and poor prognosis. Recently, recurrent gene mutations related to anorectal melanoma have been identified in a small series of cases, and this holds promise for targeted therapies, analogous to cutaneous melanoma. The purpose of this study was to analyze testing rates and prevalence of mutations in anorectal melanoma in the Dutch population.

View Article and Find Full Text PDF

Anorectal mucosal melanoma (ARMM) is exceptionally rare, highly malignant, and characterized by a poor prognosis. We present the case of a 76-year-old woman with ARMM and recurrent gastrointestinal (GI) bleeding/anemia caused by small-bowel metastases, which was successfully managed with laparoscopic resection. ARMM is an aggressive type of cancer that has the potential to metastasize to the GI tract approximately 4.

View Article and Find Full Text PDF

Anorectal melanoma: Report of two cases.

Int J Surg Case Rep

November 2024

Surgical Oncology Department, Regional Oncology Center, Mohammed VI University Hospital, Oujda, Morocco; Mohammed First University Oujda, Faculty of Medicine and Pharmacy Oujda, Oujda, Morocco.

Introduction: Anorectal melanoma (AM) is a rare and aggressive type of cancer. Its symptoms often resemble those of common benign anal conditions, such as hemorrhoids, leading to frequent delays in diagnosis. Consequently, about one-third of patients have metastases at the time of their initial diagnosis.

View Article and Find Full Text PDF

Anorectal melanoma (ARM) is a rare entity with aggressive biological behavior and poor prognosis. Clinically, ARM presents with atypical symptoms, such as anal pain and bleeding, thus often being misdiagnosed as a benign anorectal pathology and leading to delayed diagnosis. We present a case of a 73-year-old female patient with stage I ARM, treated successfully with a combination of neoadjuvant-adjuvant immunotherapy (nivolumab, an anti-PD-1 monoclonal antibody) and abdominoperineal resection.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!